Heart Disease News and Research

Latest Heart Disease News and Research

Pacific Biometrics enters into a Loan and Security Agreement to raise $4 million

Pacific Biometrics, Inc. (OTC Bulletin Board: PBME), a leading provider of specialized reference laboratory and contract research services, today announced the Company's entry into a Loan and Security Agreement with Terry M. Giles, providing for a $4 million loan (the "Loan") to the Company.

2 Sep 2009

ICD implantation reduces mortality in heart attack patients

Findings from the latest PreSCD II analysis show that patients protected against sudden cardiac death by an implantable cardioverter defibrillator (ICD) one month or more after MI showed a non-significantRemarkably," says investigator Professor Heinz Völler from the Klinik am See in Ruedersdorf, Germany, "we observed in the data a survival benefit that increased with the time interval between MI and ICD implantation."

2 Sep 2009

Combination of LIVALO and itraconazole drugs shows no adverse reactions

...

2 Sep 2009

Irregular heartbeat is a common cause of stroke

Mellanie True Hills knows personally the toll that atrial fibrillation (afib) takes. Just two years ago, with a sense of urgency about afib that only a survivor can possess, she designated September as Atrial Fibrillation Month.

2 Sep 2009

Survey on the current routine practice in CRT implantations in patients with heart failure

The European cardiac resynchronization therapy (CRT) Survey is a joint initiative taken by the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology. Its primary objective is to describe current European practice and routines associated with the implantation of a CRT device with or without an ICD (implantable cardioverter defibrillator) capability in patients with heart failure.

2 Sep 2009

Pre-hospitalization strategies will bring down mortality rate of patients with heart disorders

Mortality rate following a heart attack has fallen by more than 50% in Europe over the past 25 years. However, because only minor advances in the medical treatment of AMI are expected over the next decade, it is through organisational changes in the pre-hospital phase that mortality rate will continue this decline to below 5%.

2 Sep 2009

Strategy to enhance diabetes management across Canada

Research being driven by The University of Western Ontario that will enhance diabetes management across Canada recently received support from two of Canada's leading pharmaceutical companies in the form of a $500,000 contribution.

2 Sep 2009

The Kyoto Heart study shows positive effect of valsartan on cardiovascular outcome

The KYOTO HEART Study, which took place in Japan between January 2004 and January 2009, shows that the addition of valsartan to conventional antihypertensive treatment to improve blood pressure control is associated with an improved cardiovascular outcome in Japanese hypertensive patients at high risk of CVD events.

2 Sep 2009

SUPERVALU PHARMACIES available to administer flu shots

With an eye on convenience, cost and consumer education, SUPERVALU PHARMACIES this year has expanded its traditional flu shot offering to help ease some of the anxieties the upcoming flu season may bring.

2 Sep 2009

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA’s Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar’s efficacy and safety in the proposed patient population.

2 Sep 2009

MADIT-CRT trial reveals reduced risk of heart failure from CRT-D therapy

Asymptomatic or mildly symptomatic cardiac patients randomised to an implanted cardiac resynchronisation device with defibrillator (CRT-D) have a 34% lower risk of heart failure or death than those receiving a standard implanted cardioverter defibrillator (ICD-only) (HR 0.66,>

2 Sep 2009

St. Luke's Episcopal Hospital uses CyberKnife robotic radiosurgery system for treating tumours

St. Luke's Episcopal Hospital is the first hospital in Houston to feature the CyberKnife((R)), a noninvasive alternative to surgery for the treatment of both cancerous and non-cancerous tumors.

2 Sep 2009

Defibrillator-cardiac resynchronization therapy combination reduces heat failure risk

Patients who had a cardiac resynchronization device combined with a defibrillator (CRT-D) implanted had a 34 percent reduction in their risk of death or heart failure when compared to patients receiving only an implanted cardiac defibrillator (ICD), according to a landmark study published online today in the New England Journal of Medicine and presented today at the European Society of Cardiology Congress (ESC) in Barcelona, Spain.

2 Sep 2009

CardioWest Total Artificial Heart recipient going strong for more than 10 months

Over the last five years, Jim Hennigan has had four different hearts beating in his chest… the heart he was born with, two donor hearts and a Total Artificial Heart.

2 Sep 2009

Education and cardiac defibrillators can boost survival rates

More widespread availability of defibrillators and education of the general public could boost survival rates fourfold amongst athletes suffering cardiac arrest, a study has found. In less than half of cases, a bystander initiated cardiopulmonary reanimation. This is crucial as survival at hospital admission is 4 times higher when CPR is attempted and 10 times greater when an electric shock is delivered.

2 Sep 2009

Current European practice and routines associated with the implantation of a CRT device described

2 Sep 2009

Novo Nordisk's NCDP provides support for accurate cost and benefit assessments of preventive health

The National Changing Diabetes((R) )Program (NCDP), a program of Novo Nordisk, commends Representative Donna M. Christensen, M.D. (D-VI) and Michael C. Burgess, M.D. (R-TX) for sponsoring legislation that will lead to a more accurate assessment of the cost and benefits of preventive health, including preventing complications and delaying progression of chronic diseases such as diabetes.

From Novo Nordisk 2 Sep 2009

Primary angioplasty procedures vary in European countries

Primary angioplasty (with stent implantation) is the most effective therapy for acute myocardial infarction (AMI), but it is not available to many patients, even though most European countries have sufficient resources (ie, catheterisation laboratories) for its wider use.

2 Sep 2009

Telemedical supervision for chronic heart failure patients reduces hospital expenses

The current data confirms previous health economic evaluations: If patients with chronic heart failure are receive telemedical supervision, this means that they will require less and shorter hospital care. In this study hospital expenses dropped by around 70 percent in a year.

2 Sep 2009

PROTECT clinical study aimed at the assessment of rolofylline effects

Despite the promising findings of the PROTECT Pilot study, the larger PROTECT trial found no difference with rolofylline versus placebo with respect of the primary and main secondary end-points of the study. Although more rolofylline patients than placebo patients experienced moderate or marked dyspnea improvement at 24 and 48 hours from randomization, this was counterbalanced by a lack of effect on persistent renal impairment. Lastly, the risk of important neurological events was increased in patients on rolofylline.

2 Sep 2009

Heart Disease News and Research

Latest Heart Disease News and Research

Pacific Biometrics enters into a Loan and Security Agreement to raise $4 million

ICD implantation reduces mortality in heart attack patients

Combination of LIVALO and itraconazole drugs shows no adverse reactions

Irregular heartbeat is a common cause of stroke

Survey on the current routine practice in CRT implantations in patients with heart failure

Pre-hospitalization strategies will bring down mortality rate of patients with heart disorders

Strategy to enhance diabetes management across Canada

The Kyoto Heart study shows positive effect of valsartan on cardiovascular outcome

SUPERVALU PHARMACIES available to administer flu shots

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

MADIT-CRT trial reveals reduced risk of heart failure from CRT-D therapy

St. Luke's Episcopal Hospital uses CyberKnife robotic radiosurgery system for treating tumours

Defibrillator-cardiac resynchronization therapy combination reduces heat failure risk

CardioWest Total Artificial Heart recipient going strong for more than 10 months

Education and cardiac defibrillators can boost survival rates

Current European practice and routines associated with the implantation of a CRT device described

Novo Nordisk's NCDP provides support for accurate cost and benefit assessments of preventive health

Primary angioplasty procedures vary in European countries

Telemedical supervision for chronic heart failure patients reduces hospital expenses

PROTECT clinical study aimed at the assessment of rolofylline effects

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Heart Disease News and Research

Latest Heart Disease News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in